Background-Atrial fibrillation is an important cause of cardioembolic stroke. Oral anticoagulants (OAC) reduce stroke risk but increase the risk of serious bleeding. Left atrial appendage (LAA) procedures have been developed to isolate the LAA from circulating blood flow, as an alternative to OAC. We conducted a systematic review of the benefits and harms of surgical and percutaneous LAA exclusion procedures. Methods and Results-We searched multiple data sources, including Ovid MEDLINE, Cochrane, and Embase, through January 7, 2015. Of 2567 citations, 20 primary studies met prespecified inclusion criteria. We abstracted data on patient characteristics, stroke, mortality, and adverse effects. We assessed study quality and graded the strength of evidence using published criteria. Trials found low-strength evidence that percutaneous LAA exclusion confers similar risks of stroke and mortality as continued OAC, but this evidence was limited to the Watchman device in patients eligible for long-term OAC. Observational studies found moderate-strength evidence of serious harms with a variety of percutaneous LAA procedures. There is low-strength evidence that surgical LAA exclusion does not add significant harm during heart surgery for another indication, but evidence on stroke reduction is insufficient. Conclusions-There is limited evidence that the Watchman device may be noninferior to long-term OAC in selected patients.
A trial fibrillation (AF) is the most common cardiac arrhythmia, affecting between 2.7 and 6.1 million people in the United States. 1 The prevalence of AF increases with age and is often associated with structural heart disease and common comorbidities.
Cardioembolic strokes account for 14% to 36% of all ischemic strokes, and AF is the most important cause of cardioembolic stroke. In general, the risk of stroke in patients with nonvalvular AF is 2 to 7 times higher than in patients without AF. 2 Antithrombotic therapy with aspirin, warfarin, or one of several newer oral anticoagulants (OACs) has become the mainstay of stroke prevention in AF, but it is associated with an increased risk of bleeding.
The mechanism of thrombosis formation is stasis of blood in the left atrium, and it is currently thought that a high percentage of thromboemboli develop in the left atrial appendage (LAA). 3, 4 Given the high prevalence of AF, along with the potential risks and inconvenience of long-term (LT) OAC therapy, there is a growing interest in LAA occlusion or removal as an alternative stroke risk reduction strategy. Various procedures have been developed that attempt to isolate the LAA from circulating blood flow in an effort to reduce the risk of thromboembolic stroke. Surgery was the only option for exclusion of the LAA before 2002, but several devices designed to occlude the LAA percutaneously have since been developed. The devices currently in use include the Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO) device (Appriva Medical, Plymouth, MN), the Amplatzer device (AGA Medical Corporation/St. Jude Medical, Golden Valley, MN), the Watchman device (Boston Scientific, Natick, MA), and the LARIAT suture delivery device (SentreHeart, Redwood City, CA).
We conducted a systematic review of the benefits and harms of surgical or percutaneous LAA occlusion or removal. We use the general term LAA exclusion throughout the report to refer to either removal or isolation of the LAA, except where otherwise specified.
Methods
A protocol describing the review plan was posted to a publicly accessible website before the study was initiated. 5 The key questions and scope parameters that guided our review and synthesis of the literature is provided in Appendix I in the Data Supplement.
To identify relevant articles, we searched Ovid MEDLINE, Embase, the Cochrane databases, and the FDA Devices database from database inception through January 7, 2015 , using a search strategy that included terms for AF, cardiovascular procedures, and names of LAA devices and exclusion techniques (Appendix II in the Data Supplement). The search strategy was developed by 2 research librarians, using the instrument for Peer Review of Search Strategies. 6, 7 We further examined the bibliographies of relevant articles; consulted technical experts for additional studies; searched ClinicalTrials.gov, the Conference Abstracts database, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP); and contacted device manufacturers (Appendix III in the Data Supplement) to identify in-progress or unpublished trial data. We reviewed titles and abstracts for relevance to the key questions using prespecified eligibility criteria. At the full-text screening stage, 2 independent reviewers concurred on final inclusion/exclusion decisions, with input from a third investigator to resolve questions and reach consensus.
We included controlled clinical trials to assess the effectiveness of percutaneous LAA exclusion procedures. In addition to controlled trials, cohort studies with or without a control population were included to examine harms of percutaneous interventions. After an initial survey of the literature, we found that there were several larger cohort studies providing harms data and, therefore, set a sample size cut off of ≥50 patients for inclusion.
Given that surgical LAA exclusion procedures were usually done in the context of heart surgery and that the harms related to LAA exclusion would be difficult to distinguish from those of the heart surgery itself, we only included controlled clinical trials or cohort studies with a control population of patients who received heart surgery but no LAA exclusion to assess benefits and harms of surgical LAA exclusion. From each study, we abstracted study design, objectives, setting, subject eligibility criteria, years of enrollment, sample size, population demographics and clinical characteristics, the study and comparator interventions, important cointerventions, duration of follow-up, health outcomes, and adverse events. A second author reviewed the entries for accuracy.
Two reviewers (among N.N., D.K., J.P., and M.F.) independently assessed study quality and assigned each trial, an overall rating of low, high, or unclear risk of bias, using a tool developed by the Cochrane Collaboration (Appendix IV in the Data Supplement). 8 For evaluating cohort studies of surgical LAA interventions, we used the NewcastleOttawa criteria to assess methodological rigor and consider potential sources of bias 9 but did not assign overall quality ratings because validated criteria are not currently available for rating observational studies.
We qualitatively synthesized the evidence on the benefits and harms of LAA exclusion. Clinical heterogeneity and the small number of trials precluded the feasibility of combining the findings in meta-analysis.
We used a method developed by the Agency for Healthcare Research and Quality 10 that considers the consistency, coherence, and applicability of the body of evidence, as well as the internal validity of individual studies, to classify the overall strength of evidence for each outcome as follows: high, further research is unlikely to change our confidence on the estimate of effect; moderate, further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low, further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; and insufficient, any estimate of effect is uncertain.
Results
We reviewed 2567 titles and abstracts, including 2469 from the electronic search and an additional 98 from reviewing reference lists and searching manually for recent, ongoing, or unpublished studies. We selected 207 articles for full-text review, of which 20 primary studies met our inclusion criteria (Figure) . We also identified 5 systematic reviews of the effectiveness of percutaneous LAA devices. We contacted 7 device companies to request information about unpublished studies but received no response (Appendix III in the Data Supplement).
Percutaneous LAA Interventions
Two randomized controlled trials (RCTs) compared the Watchman Left Atrial Appendage Closure Device (Atritech, Inc, North Plymouth, MN) to warfarin therapy (Table 1) . Both the trials were determined to have a low risk of bias. Inclusion into the Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (PROTECT-AF) [12] [13] [14] trial required subjects to have nonvalvular AF and a CHADS 2 27 score of at least 1, whereas the Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients with Atrial Fibrillation Versus Long-Term Warfarin Therapy (PREVAIL) 11 trial enrolled subjects with higher risk of stroke; patients were excluded from these trials if they had contraindication to warfarin therapy, recent stroke, or a patent foramen ovale/atrial septal defect. The PROTECT-AF trial included 463 interventions and 244 control patients with nonvalvular AF and excluded patients with low risk of stroke (CHADS 2 =0). The device was successfully deployed in 88% (408/463) of patients, although it was not attempted in 14 patients. Successful closure was obtained in 92% (355/385) at 6 months and only 3.6% (14/385) of patients who underwent device implantation remained on warfarin after 3 months; warfarin was discontinued with complete closure or if residual peridevice flow was <5 mm width on surveillance transesophageal echocardiogram (TEE). 13, 14 The control arm was within therapeutic international normalized ratio (INR) range 66% of the time.
WHAT IS KNOWN
• Anticoagulation is currently the standard of care to prevent cardioembolic stroke in patients with atrial fibrillation.
• The Watchman left atrial appendage closure device was found to be largely noninferior to standard therapy in patients with nonvalvular atrial fibrillation who are candidates for anticoagulation.
WHAT THE STUDY ADDS
• There is no evidence to recommend percutaneous left atrial appendage exclusion in patients with atrial fibrillation who are ineligible for therapeutic anticoagulation; randomized trials have not been performed.
• In the few published case series available, the overall risk of serious adverse events with percutaneous device therapy is ≈1 in 15 patients.
• Surgical left atrial appendage exclusion does not seem to be associated with increased harm when performed during cardiac surgery for another indication, but there is insufficient evidence to compare the efficacy of this procedure to anticoagulation therapy.
There was no difference in a composite primary efficacy end point including ischemic/hemorrhagic stroke, cardiovascular/unexplained death, and systemic embolism with 3.0 (1.9-4.5) events per 100 patient-years in the LAA exclusion group versus 4.9 (2.8-7.1) events per 100 patientyears in the warfarin group (rate ratio, 0.62; 0. 35-1.25) . Cumulative events at 2.3 years of mean follow-up (SD, 1.1 years; median, 2.4; range, 0.5-9 years) were also similar with 3.0 (2.15-4.3) events per year in the LAA exclusion group versus 4.3 (2.6-5.9) events per year in the warfarin group. Overall, LAA exclusion was noninferior to warfarin therapy in patients who were candidates for anticoagulation in PROTECT-AF trial. 13, 14 In a subset of patients in the PROTECT-AF trial, quality of life modestly improved in the intervention group on some subscales. However, the absolute differences were small, and the findings subject to bias, given lack of patient blinding and differential rates of follow-up in each group. 12 The PREVAIL trial enrolled 407 subjects (269 assigned to LAA exclusion and 138 assigned to warfarin therapy) and followed them for an average of 11.8 months (SD, 5.8 months; range, 0.03-25.9 months). 11 Patients were slightly older and had a higher risk of stroke than the population included in the PROTECT-AF trial. Device deployment was successful in 95.1% (252/269) of patients. At 6 months, device closure was demonstrated in 98.3% (235/239), although 11.2% (30/269) refused follow-up TEE.
The PREVAIL trial did not meet its target of noninferiority for overall efficacy, although event rates were low and numerically comparable to both arms. Overall mortality was 2.6% in the LAA exclusion group versus 2.2% in the warfarin group. A composite outcome of death, ischemic/hemorrhagic stroke, or systemic embolism occurred in 5.2% of the LAA exclusion group and in 2.9% of the warfarin group. 11 We found 2 trials and 11 observational studies reporting harms data (Table 1) . Serious periprocedural adverse events were reported in 1.6% to 13.6% of patients. Overall, the rate of periprocedural harms occurring within 7 days of device placement was 6.5% (98/1506). The types of periprocedural events most commonly reported included pericardial effusions with and without associated tamponade, bleeding, device thrombus, and device embolization. ACP indicates amplatzer cardiac plug; AE, adverse event; AF, atrial fibrillation; ASD, atrial septal defect; CAD, coronary artery disease; CHADS 2 , stroke risk score in AF (congestive heart failure, hypertension, age 75+ years, diabetes mellitus, and stroke/TIA); CHA 2 DS 2 -VASc, stroke risk score in AF that includes CHADS 2 with age in 2 categories and vascular disease; CHF, congestive heart failure; DM, diabetes mellitus; GI, gastrointestinal; HAS-BLED, score that estimates risk of major bleeding for patients on anticoagulation for atrial fibrillation; HTN, hypertension; INR, international normalized ratio; LAA, left atrial appendage; LT-OAC, long-term oral anticoagulation therapy; LVEF, left ventricular ejection fraction; n, number (of); NR, not reported; PFO, patent foramen ovale; PLAATO, percutaneous left atrial appendage transcatheter occlusion; QoL, quality of life; TEE, transesophageal echocardiography; TIA, transient ischemic attack; VATS, video-assisted thoracoscopy; and VSD, ventricular septal defect.
*Total serious AEs in our report differs from primary source because we included procedure-related strokes and pericardial effusions requiring any intervention. †Implies complete closure or residual peridevice flow <5 mm in width on TEE. Procedural Success: Deployment, n (%) of Attempted; Closure, n (%) Assessed by TEE Two trials examined harms associated with placement of the Watchman device. 11, 13 In PROTECT-AF trial, 10.6% (49/463) of patients experienced a safety event with 55.1% (27/49) of those occurring on the day of the procedure. Significant pericardial effusion followed by major bleeding accounted for most of these events. The authors note the rate of pericardial effusion declined with operator experience. In contrast, the safety event rate was much lower (2.2%) in the more recently conducted PREVAIL trial. 11 Adverse event rates were similar in the single-center 15, 17, [20] [21] [22] 24 and the multicenter studies. 18, 23, 25, 26 We did not find robust comparative effectiveness data to directly assess the relative rates of serious safety events according to the device used. However, there were serious periprocedural events, including death or need for emergent surgery reported for all included devices (Table 1) . Currently, there is no RCT data available to compare deployment success, LAA exclusion achieved, or health outcome benefits among the different devices.
Over the LT in observational studies, patients had low rates of stroke and bleeding, and there were no reported technical device failures. However, data on longer-term safety from the observational studies are limited, in part, by high rates of attrition, 23 lack of information about the loss to follow-up, 15,18-21 wide variation in follow-up duration (6 months to 5 years), and the lack of a consistent standard for adverse events reporting.
Although the 2 RCTs excluded patients who were ineligible to receive anticoagulant therapy, 7 of 11 observational studies included patients who were ineligible for LT-OAC therapy. In most of these studies, the LT rates of stroke were ≈2.1% (12/565) during the course of 6 to 24 months of follow-up. 15, 20, 23, 24, 26 Surgical LAA Interventions Three RCTs and 2 observational studies evaluated the effectiveness of surgical LAA exclusion compared with usual care ( Table 2) . Each of the randomized trials involved patients undergoing cardiac surgery and cardiopulmonary bypass for another indication (coronary artery bypass grafting or valve surgery) and were small studies designed to determine the safety and efficacy of the procedure. [28] [29] [30] The RCTs, although at low risk of bias, were underpowered for determining the clinical effectiveness of this procedure. Both the observational studies demonstrated no significant difference in stroke-free survival during the course of their follow-up, but important data such as information about anticoagulation use among the groups was lacking. 32, 33 One study evaluated success of surgical LAA closure as determined by postoperative TEE after a mean time of 8.1±12 months. 31 Of 137 patients who underwent surgical excision, only 40% of all closures were successful. Successful LAA exclusion was found to be more common with excision (73%, P<0.001) than suture exclusion (23%, P>0.001) or stapler exclusion (0%, P=0.002). Another small study compared adverse events between anterior thoracotomy and video-assisted thorascopic surgery approaches to LAA exclusion and found no significant differences. 34 There were no significant differences in complication rates between the LAA exclusion and control groups in any of the surgical studies (Table 2) .
28-30,32,33

Discussion
We systematically reviewed the literature and found 13 studies assessing the benefits and harms of percutaneous approaches to LAA exclusion and 7 studies assessing the benefits and harms of surgical LAA exclusion. The key findings and strength of evidence supporting these findings is listed in Table 3 . Overall, there is limited evidence on 1 device that percutaneous LAA exclusion may be an effective alternative to LT oral anticoagulation in selected patients who are closely followed and in whom procedural success is sustained, although there are significant procedure-related harms. There is insufficient evidence to assess the benefits of surgical LAA exclusion, although these procedures do not seem to be associated with a significant increase in harms over the heart surgery during which the procedures are typically performed.
There is low-strength evidence that percutaneous LAA exclusion with the Watchman device is associated with a similar risk of LT stroke and mortality as continued oral anticoagulation therapy. Most patients who received the Watchman device were able to discontinue OAC therapy after undergoing a follow-up TEE showing persistent closure of the LAA at 3 to 6 months. However, there is moderate-strength evidence that a substantial proportion of patients experienced serious periprocedural harms. Overall, ≈1 in 15 patients experienced a serious adverse event during percutaneous LAA exclusion procedures. There is insufficient evidence to determine whether factors such as operator experience, patient selection criteria, or choice of device can modify these risks.
There are several clinical situations in which percutaneous LAA exclusion may be a potentially attractive option, although the data directly supporting the use in these circumstances is limited. First, LAA exclusion might be especially attractive for patients who are unable to take OACs. However, the trial data most closely apply to patients who do not have contraindications to LT-OAC therapy. In these trials, warfarin was used typically for 3 to 6 months until device endothelialization, and LAA closure was achieved.
Several observational studies included patients ineligible for LT-OAC therapy, 17, 20, 21, 23, 24, 26 and while most found low rates of stroke over 1 to 2 years of follow-up, at least 1 study found higher incidence of stroke during a longer follow-up period. 17 Of note, even though warfarin was not used, patients in most of these studies used dual antiplatelet therapy for a duration ranging from 4 weeks to 6 months. Dual antiplatelet therapy in the population of patients with AF who have increased risk of stroke and for whom vitamin-K antagonists are unsuitable is associated with a 2.0% risk of major bleeding annually. 35 It is notable that in a large study of warfarin versus dual antiplatelet therapy for prevention of stroke in AF, the risk of major bleeding was similar between the groups (2.21% annual risk of stroke versus 2.42%, respectively; RR, 1.10; 95% CI, 0.83-1.45; P=0.53). 36 Thus, as long as the protocol for the use of LAA closure devices includes dual antiplatelet therapy for any significant length of time, it may not be an attractive option for patients who are at high risk for bleeding complications and who do not wish to take, or have contraindications to, warfarin. The second clinical circumstance in which LAA exclusion might provide a useful alternative is for patients who might otherwise accrue a more substantial bleeding risk from OAC therapy over longer-time horizons. In the PROTECT-AF trial, most events in the LAA exclusion group accrued earlier in the study, whereas event rates in the control group increased steadily (although remained lower overall) during 3 years of follow-up.
14 Theoretically, then, it is possible that the risks of LT anticoagulation might eventually offset the near-term risks of LAA exclusion device placement. However, this has not been tested empirically and, given that not all cardioembolic strokes in AF originate in the left atrial appendage, it is certainly possible that LT stroke risk in patients receiving a device who remain off anticoagulation may increase.
Third, some patients may simply prefer the placement of an LAA exclusion device over the inconvenience of LT OAC. Policy makers will need to consider whether routine availability of periprocedural LAA exclusion for preference-sensitive indications is warranted. There are a variety of devices being used for LAA exclusion, but there is inadequate evidence that the efficacy and safety of each of these devices are similar enough to comfortably extrapolate data from 1 device and apply to the use of a different device. Although the techniques used for many of the devices are similar, there are still important differences perhaps most notably for the Lariat device, which takes an epicardial approach to snaring and externally excluding the LAA. For the time being, the evidence for device efficacy applies most closely to the Watchman device, and there is insufficient evidence to determine the efficacy of other devices.
Finally, it should be noted that the decision to discontinue anticoagulant therapy in the included studies was based on demonstrated LAA closure on follow-up TEE. Up to 4% to 6% of patients had continued evidence of LAA blood flow at 6 months, and this may be an underestimate because these figures do not account for the proportion of patients in trials and observational studies who refused follow-up TEE. The benefits and harms of percutaneous LAA exclusion in patients for whom TEE monitoring is infeasible remain essentially unknown.
We found insufficient evidence to determine the efficacy of surgical LAA exclusion in reducing stroke. We found lowstrength evidence that surgical LAA exclusion in the context of heart surgery performed for another indication is unlikely to be associated with significant incremental harm. However, data from 1 trial and 1 observational study suggest that a relatively high proportion of patients have persistent LAA blood flow detected on follow-up. Therefore, until more data become available, surgical LAA exclusion should likely not influence decision making about future OAC therapy. 28, 31 Our findings corroborate and add to several recent systematic reviews. [37] [38] [39] [40] A recently published patient-level meta-analysis of the Watchman device 41 similarly found no significant difference in risk of stroke between percutaneous LAA exclusion using the Watchman device and LT warfarin AE indicates adverse event; AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; CVA, cerebrovascular accident; DM, diabetes mellitus; GI, gastrointestinal; HTN, hypertension; Hx, history (of); IABP, intra-aortic balloon pump; LAA, left atrial appendage; MI, myocardial infarction; n, number (of); NR, not reported; NS, not significant; PSM, propensity score matching; RR, relative risk; TEE, transesophageal echocardiography; TIA, transient ischemic attack; and VATS, video-assisted thoracoscopy.
*Baseline characteristics were well balanced between the groups, with the exception that there was more valvular disease (P=0.01) and a trend toward more valve surgery (P=0.06) in the occlusion arm. 41 In contrast to previous reviews, we examined both percutaneous and surgical approaches to LAA exclusion. Also, we systematically examined data from trials and observational studies to assess harms, to better understand applicability to different patient populations (including those ineligible for LT-OAC therapy), and to identify patient or procedure-related factors that might modify benefits or harms of procedures. Although we, like others, have identified gaps in evidence, we think our explicit discussion about how the evidence does and does not apply to different devices and patient populations, along with a comprehensive description of harms will help inform shared decision-making discussions between patients and physicians contemplating increasingly available procedure-based therapies.
Although we adhered to published standards for systematic review conduct, there are several potential methodologic limitations to note. First, we excluded non-English language studies. There is empirical data, however, suggesting that reviews restricted to English language studies are largely concordant with reviews without language restrictions. 42 Second, we excluded observational studies enrolling fewer than 50 participants. However, we felt that these typically singlecenter studies with very small denominators were unlikely to yield reliable information about rates of harms or procedural success.
There are significant limitations in this body of evidence as a whole, and these are noted throughout this article. Clearly, one of the biggest limitations is simply the relative paucity of methodologically rigorous studies examining the efficacy of percutaneous and surgical LAA exclusion. Trials of ACP indicates amplatzer cardiac plug; CI, confidence interval; LAA, left atrial appendage; LT-OAC, long-term oral anticoagulation therapy; n, number (of); PLAATO, percutaneous left atrial appendage transcatheter occlusion; RCT, randomized controlled trial; and RR, relative risk.
*The overall quality of evidence for each outcome is based on the consistency, coherence, and applicability of the body of evidence, as well as the internal validity of individual studies. The strength of evidence is classified as follows 10 : high, further research is unlikely to change our confidence on the estimate of effect; moderate, further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low, further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; and insufficient, any estimate of effect is uncertain.
percutaneous LAA interventions were limited to studies of the Watchman device in patients who were eligible for LT warfarin therapy. Trials of surgical LAA interventions were few and limited by sample size. Several studies that should add substantively to this body of evidence are underway, including a large RCT of surgical interventions 43 ; studies of recently developed percutaneous devices (LAmbre 44 and Occlutech 45 ); and a trial comparing Watchman with Apixaban in patients ineligible for warfarin therapy. 46 
Conclusions
Overall, there is limited evidence that percutaneous LAA exclusion may be an effective alternative to LT oral anticoagulation in selected patients who are closely followed and in whom procedural success is sustained. However, only 1 percutaneous device has been studied rigorously in trials, and percutaneous LAA exclusion has been associated with high rates of serious procedure-related harms in many studies. There is insufficient evidence to assess the benefits of surgical LAA exclusion. Although surgical LAA exclusion does not seem to be associated with a significant increase in harms over the heart surgery during which the procedures are typically performed, rates of procedural success may be low. Overall, there is insufficient evidence to support the routine use of surgical LAA exclusion to reduce stroke risk or future need for anticoagulant therapy. There are several ongoing studies that should add substantively to this body of evidence during the next several years.
